Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 5/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | F11 | P03951 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 6/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | F2 | P00734 | 2/20 | 0.31 |
| ▸ | PLAU | P00749 | 2/20 | 0.31 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.31 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.31 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30379575 | 1.00 | DGAT1 (0.35) | DGAT1MAPTNPC1F11ELANE | |
| SCHEMBL22532250 | 0.91 | DGAT1 (0.35) | DGAT1MAPTNPC1F11ELANE | |
| SCHEMBL19950154 | 0.89 | ELANE (0.38) | DGAT1ELANEF2PLAU | |
| SCHEMBL26690266 | 0.88 | CFD (0.37) | DGAT1MAPTNPC1ELANEF2 | |
| SCHEMBL30758748 | 0.88 | CFD (0.37) | DGAT1MAPTNPC1ELANEF2 | |
| SCHEMBL30380522 | 0.82 | DGAT1 (0.34) | DGAT1MAPTNPC1F11ALDH1A1 | |
| SCHEMBL24150198 | 0.82 | DGAT1 (0.34) | DGAT1MAPTNPC1F11ALDH1A1 | |
| SCHEMBL21055191 | 0.79 | DGAT1 (0.36) | DGAT1MAPTNPC1 | |
| SCHEMBL17919409 | 0.79 | NPC1 (0.32) | DGAT1MAPTNPC1 | |
| SCHEMBL16532624 | 0.79 | ELANE (0.52) | DGAT1MAPTNPC1ELANEF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-02-16 | — | — | US | disclosed |
| WO-2021262596-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, HRAS | DGAT1 2417/4885MAPT 4203/4885NPC1 2575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.